In:
Catheterization and Cardiovascular Interventions, Wiley, Vol. 100, No. 4 ( 2022-10), p. 535-543
Abstract:
The aim of this study was to determine the role of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in the prognostication of patients ≥80 years of age undergoing percutaneous coronary intervention (PCI). Background Elderly patients with coronary artery disease in need of PCI represent a growing patient population. Advanced risk prediction in this frail and comorbid patient population is important. Methods A total of 460 consecutive patients ≥80 years of age undergoing PCI for acute (ACS) or chronic coronary syndromes (CCS) at the University Hospital Zurich, Switzerland, between January 2016 and December 2018 and with available baseline NT‐proBNP levels were included in the analysis. Patients were stratified according to baseline NT‐proBNP levels. The primary endpoint was all‐cause mortality at a median follow‐up of 33 (interquartile range: 3–392) days. Results Median baseline NT‐proBNP levels were 1411 (457–3984) ng/L. All‐cause mortality was 7.8% in the lowest and 27.8% in the highest NT‐proBNP quartile group ( p 〈 0.001). In patients with ACS, all‐cause mortality was 4.8% and 30.4% in the lowest and the highest NT‐proBNP quartile ( p 〈 0.001), and corresponding rates in patients with CCS were 11.1% and 22.2% ( p = 0.38). In multivariable Cox regression analysis, baseline NT‐proBNP levels were independently associated with an increased risk of all‐cause mortality (adjusted hazard ratio: 1.00, 95% confidence interval: 1.00–1.00, p = 0.04). Conclusions Baseline NT‐proBNP levels were identified as independent predictor of mortality in elderly (≥80 years) patients undergoing PCI. Hence, baseline NT‐proBNP allows for the identification of a high‐risk elderly patient subset.
Type of Medium:
Online Resource
ISSN:
1522-1946
,
1522-726X
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
2001555-0
